NASDAQ:PRFX PainReform (PRFX) Stock Price, News & Analysis $0.74 -0.07 (-8.69%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About PainReform Stock (NASDAQ:PRFX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PainReform alerts:Sign Up Key Stats Today's Range$0.68▼$0.7750-Day Range$0.21▼$1.5952-Week Range$0.53▼$20.16Volume391,856 shsAverage Volume167,130 shsMarket Capitalization$426,474.00P/E RatioN/ADividend YieldN/APrice Target$2.00Consensus RatingBuy Company OverviewPainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. PainReform Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks51st Percentile Overall ScorePRFX MarketRank™: PainReform scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPainReform has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePainReform has received no research coverage in the past 90 days.Read more about PainReform's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of PainReform is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PainReform is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPainReform has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about PainReform's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.42% of the float of PainReform has been sold short.Short Interest Ratio / Days to CoverPainReform has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PainReform has recently decreased by 11.38%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPainReform does not currently pay a dividend.Dividend GrowthPainReform does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.42% of the float of PainReform has been sold short.Short Interest Ratio / Days to CoverPainReform has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PainReform has recently decreased by 11.38%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for PainReform this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added PainReform to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PainReform insiders have not sold or bought any company stock.Percentage Held by Insiders34.40% of the stock of PainReform is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 37.28% of the stock of PainReform is held by institutions.Read more about PainReform's insider trading history. Receive PRFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter. Email Address PRFX Stock News HeadlinesPainReform (NASDAQ:PRFX) Trading 11% Higher - Here's WhyOctober 19, 2024 | americanbankingnews.comPainReform Shares Are Trading Lower Today: What's Going OnSeptember 11, 2024 | msn.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110September 11, 2024 | globenewswire.comPainReform Announces Exercise of Warrants for $1.58 Million Gross ProceedsSeptember 10, 2024 | globenewswire.comPainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy ProceduresAugust 21, 2024 | finance.yahoo.comPainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy StudyAugust 20, 2024 | globenewswire.comBuy Rating Justified by PainReform’s Promising PRF-110 with Competitive Edge and Positive Clinical DataAugust 17, 2024 | markets.businessinsider.comSee More Headlines PRFX Stock Analysis - Frequently Asked Questions How have PRFX shares performed this year? PainReform's stock was trading at $2.75 at the beginning of 2024. Since then, PRFX stock has decreased by 73.3% and is now trading at $0.7353. View the best growth stocks for 2024 here. How were PainReform's earnings last quarter? PainReform Ltd. (NASDAQ:PRFX) issued its quarterly earnings data on Thursday, August, 15th. The company reported ($0.40) earnings per share for the quarter. When did PainReform's stock split? Shares of PainReform reverse split before market open on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did PainReform IPO? PainReform (PRFX) raised $20 million in an initial public offering (IPO) on Tuesday, September 1st 2020. The company issued 2,500,000 shares at $8.00 per share. Maxim Group and Joseph Gunnar served as the underwriters for the IPO. How do I buy shares of PainReform? Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of PainReform own? Based on aggregate information from My MarketBeat watchlists, some other companies that PainReform investors own include Predictive Oncology (POAI), Bank of America (BAC), Ford Motor (F), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Zomedica (ZOM). Company Calendar Last Earnings8/15/2024Today10/23/2024Next Earnings (Estimated)11/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRFX CUSIPN/A CIK1801834 Webwww.painreform.com Phone972-3717-7051FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+172.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($36.8326) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-450.64% Return on Assets-241.33% Debt Debt-to-Equity RatioN/A Current Ratio0.61 Quick Ratio1.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$27.87 per share Price / Book0.03Miscellaneous Outstanding Shares580,000Free Float379,000Market Cap$426,474.00 OptionableNot Optionable Beta0.54 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:PRFX) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.